Silver Book Fact

A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s disease and $12,294/QALY for patients with advanced disease.

Hoerger T, Bala M, Rowland C, Greer M, et al. Cost Effectiveness of Pramipexole in Parkinson’s Disease in the U.S. Pharmacoeconomics. 1998; 14(5): 541-57. http://www.ncbi.nlm.nih.gov/pubmed/10344917

Reference

Title
Cost Effectiveness of Pramipexole in Parkinson’s Disease in the U.S.
Publication
Pharmacoeconomics
Publication Date
1998
Authors
Hoerger T, Bala M, Rowland C, Greer M, et al.
Volume & Issue
Volume 14, Issue 5
Pages
541-57
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Deep Brain Stimulation for Parkinson’s Adds QALYs and Saves Money
     
  • Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 total cost of care (for all payers) for all people…  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2050 Medicare costs for people with the disease would be…  
  • Impact of a 5-Year Delay in Onset by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050